Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Stephen Eeden and Reina Haque.
Stephen Eeden
Connection Strength
1.757
Reina Haque
  1. Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. Br J Cancer. 2017 Oct 10; 117(8):1233-1240.
    View in: PubMed
    Score: 0.287
  2. Association of body mass index and prostate cancer mortality. Obes Res Clin Pract. 2014 Jul-Aug; 8(4):e374-81.
    View in: PubMed
    Score: 0.217
  3. Preventive care and health behaviors among overweight/obese men in HMOs. Am J Manag Care. 2012 Jan; 18(1):25-32.
    View in: PubMed
    Score: 0.194
  4. Correlates of prostate-specific antigen testing in a large multiethnic cohort. Am J Manag Care. 2009 Nov; 15(11):793-9.
    View in: PubMed
    Score: 0.167
  5. Risk of diabetes complications among those with diabetes receiving androgen deprivation therapy for localized prostate cancer. Cancer Causes Control. 2018 Aug; 29(8):785-791.
    View in: PubMed
    Score: 0.076
  6. Correlates of screening sigmoidoscopy use among men in a large nonprofit health plan. Cancer. 2007 Jul 15; 110(2):275-81.
    View in: PubMed
    Score: 0.071
  7. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer. J Urol. 2017 06; 197(6):1448-1454.
    View in: PubMed
    Score: 0.069
  8. Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer. World J Urol. 2016 Dec; 34(12):1611-1619.
    View in: PubMed
    Score: 0.065
  9. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol. 2015 Jun; 193(6):1956-62.
    View in: PubMed
    Score: 0.060
  10. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol. 2014 May 01; 32(13):1324-30.
    View in: PubMed
    Score: 0.057
  11. Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study. Prostate. 2013 Sep; 73(13):1371-7.
    View in: PubMed
    Score: 0.053
  12. Impact of type 2 diabetes on lower urinary tract symptoms in men: a cohort study. BMC Urol. 2013 Feb 20; 13:12.
    View in: PubMed
    Score: 0.053
  13. A comparison of lifestyle and behavioral cardiovascular disease risk factors between Asian Indian and White non-Hispanic men. Ethn Dis. 2012; 22(2):168-74.
    View in: PubMed
    Score: 0.049
  14. Evaluating racial/ethnic disparities in lower urinary tract symptoms in men. J Urol. 2012 Jan; 187(1):185-9.
    View in: PubMed
    Score: 0.048
  15. Regular nonsteroidal anti-inflammatory drug use and erectile dysfunction. J Urol. 2011 Apr; 185(4):1388-93.
    View in: PubMed
    Score: 0.046
  16. Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men's Health Study. PLoS One. 2010 Jan 15; 5(1):e8736.
    View in: PubMed
    Score: 0.042
  17. Red wine consumption and risk of prostate cancer: the California men's health study. Int J Cancer. 2010 Jan 01; 126(1):171-9.
    View in: PubMed
    Score: 0.042
  18. Generational status and duration of residence predict diabetes prevalence among Latinos: the California Men's Health Study. BMC Public Health. 2009 Oct 19; 9:392.
    View in: PubMed
    Score: 0.042
  19. Racial disparities in erectile dysfunction among participants in the California Men's Health Study. J Sex Med. 2009 Dec; 6(12):3433-9.
    View in: PubMed
    Score: 0.042
  20. Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study. Drugs. 2009 Jul 30; 69(11):1445-57.
    View in: PubMed
    Score: 0.041
  21. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2007 Nov; 16(11):2218-25.
    View in: PubMed
    Score: 0.036

© 2025 Kaiser Permanente

Your Privacy Choices